• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by Coelho Mary Theresa

    8/17/21 4:46:12 PM ET
    $AZRX
    Major Pharmaceuticals
    Health Care
    Get the next $AZRX alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Coelho Mary Theresa

    (Last) (First) (Middle)
    C/O AZURRX BIOPHARMA, INC.
    777 YAMATO ROAD, SUITE 502

    (Street)
    BOCA RATON FL 33431

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    08/11/2021
    3. Issuer Name and Ticker or Trading Symbol
    AzurRx BioPharma, Inc. [ AZRX ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24.1 - Power of Attorney
    No securities are beneficially owned.
    /s/ Mary Theresa Coelho 08/17/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AZRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZRX

    DatePrice TargetRatingAnalyst
    8/2/2021$2.50 → $2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AZRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

      BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("First Wave" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that it will begin operating under its new corporate name, First Wave BioPharma, Inc., effective today upon the completion of certain filings with the Delaware Secretary of State. The Company's common shares will commence trading on the Nasdaq Capital Market under the new ticker symbol "FWBI" and CUSIP number (33749P101) at the market open on September 22, 2021. Formerly known as AzurRx BioPharma, Inc., the

      9/21/21 12:47:42 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

      BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company's website, is as follows: Dear Shareholders, It is with great excitement and enthusiasm that I write to you, the shar

      9/14/21 7:30:00 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

      AzurRx BioPharma to be renamed "First Wave BioPharma" and trade under new NASDAQ ticker symbol, "FWBI" Three IBD clinical indications, including ulcerative colitis and Crohn's disease, added to GI therapeutic pipeline with multiple near-term inflection points Conference call scheduled for today at 8:30 a.m. ET BOCA RATON, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a definitive agreement to acquire First Wave Bio, Inc. ("First Wave Bio") in a stock and cash transaction valued

      9/13/21 6:00:00 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Financials

    Live finance-specific insights

    See more
    • AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

      AzurRx BioPharma to be renamed "First Wave BioPharma" and trade under new NASDAQ ticker symbol, "FWBI" Three IBD clinical indications, including ulcerative colitis and Crohn's disease, added to GI therapeutic pipeline with multiple near-term inflection points Conference call scheduled for today at 8:30 a.m. ET BOCA RATON, Fla., Sept. 13, 2021 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered a definitive agreement to acquire First Wave Bio, Inc. ("First Wave Bio") in a stock and cash transaction valued

      9/13/21 6:00:00 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Coelho Mary Theresa

      4 - AzurRx BioPharma, Inc. (0001604191) (Issuer)

      9/13/21 8:08:11 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by Coelho Mary Theresa

      3 - AzurRx BioPharma, Inc. (0001604191) (Issuer)

      8/17/21 4:46:12 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Pennington James

      4 - AzurRx BioPharma, Inc. (0001604191) (Issuer)

      7/9/21 5:11:55 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on AzurRx BioPharma with a new price target

      HC Wainwright & Co. reiterated coverage of AzurRx BioPharma with a rating of Buy and set a new price target of $2.00 from $2.50 previously

      8/2/21 6:16:37 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • Roth Capital reiterated coverage on AzurRx BioPharma with a new price target

      Roth Capital reiterated coverage of AzurRx BioPharma with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      4/1/21 9:17:16 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • HC Wainwright & Co. reiterated coverage on AzurRx BioPharma with a new price target

      HC Wainwright & Co. reiterated coverage of AzurRx BioPharma with a rating of Buy and set a new price target of $2.50 from $3.50 previously

      4/1/21 6:44:15 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Leadership Updates

    Live Leadership Updates

    See more
    • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

      BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

      8/16/21 8:00:00 AM ET
      $AZRX
      $BCPC
      $BDSI
      Major Pharmaceuticals
      Health Care
      Major Chemicals
      Industrials
    • AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors

      DELRAY BEACH, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the appointment of James Sapirstein, President and CEO, as chairman of the company’s board of directors, effective immediately. Mr. Sapirstein succeeds Mr. Edward J. Borkowski, who joined the AzurRx board in May 2015 and has served as chairman since April 2016. Mr. Borkowski will remain as lead independent director of the board of directors. “AzurRx is on the verge of several important inflection points, and

      2/24/21 7:00:00 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed

      SC 13D/A - AzurRx BioPharma, Inc. (0001604191) (Subject)

      2/10/21 9:54:48 AM ET
      $AZRX
      Major Pharmaceuticals
      Health Care

    $AZRX
    SEC Filings

    See more
    • AzurRx BioPharma, Inc. filed SEC Form 8-K: Other Events

      8-K - First Wave BioPharma, Inc. (0001604191) (Filer)

      9/28/21 5:16:00 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - First Wave BioPharma, Inc. (0001604191) (Filer)

      9/21/21 4:38:38 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care
    • AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AzurRx BioPharma, Inc. (0001604191) (Filer)

      9/14/21 5:12:55 PM ET
      $AZRX
      Major Pharmaceuticals
      Health Care